Curriculum Registration

On the front lines - Managing CRS in the Emergency Department

Credits Available: 4.25 AMA PRA Category 1 Credit™; ABIM MOC

Description: Rigorous clinical research has led to the discovery of novel immunologic therapies. Chimeric antigen receptor T cell (CAR T-cell) therapy has shown impressive outcomes but is associated with a significant risk of adverse events (AEs), chiefly cytokine release syndrome (CRS). Bispecific antibodies act through a similar mechanism of action but offer a lower risk of CRS. These AEs may require immediate management, which may occur in the emergency department (ED) setting.

Given the novelty and specialty nature of bispecific antibody and CAR T-cell therapies, ED clinicians face several challenges in the practical management of patients receiving these therapies. Similarly, given the breadth of conditions treated with these therapies, ED clinicians may face difficulties knowing which patient populations are at risk. While CAR T therapies are approved for hematologic malignancies, bispecific antibodies are approved for many indications including hematologic malignancies, non-small cell lung cancer, uveal melanoma, hemophilia A, and neovascular macular edema. This collaborative social learning platform establishes a network of providers who can create a sustainable network of providers who can continue to support each other following this experience in implementing their practice action plans aimed at improving the care provided to patients on CAR T or bispecific therapies.

John Hopkins Medicine Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:
Forgot Password

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Emergency Medicine, Oncology
Group Leader

Matthew Lunning

University of Nebraska Medical Center
Associate Professor

I work primarily with lymphoma patients in the newly diagnosed and rel/ref settings. I have been active in the development and participation in CAR-T cell trials in multiple NHL diagnoses.

 

Group Co-Leader

Katherine Byar

Nebraska Medicine
Hematological Malignancy Nurse Practitioner

Katherine Byar, MSN, APRN-BC, BMTCN® is an malignant hematology/oncology nurse practitioner at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska.

Ms. Byar received her Master of Science in Nursing at the University of Nebraska Medical Center. She is certified as an Adult Nurse Practitioner and a Bone Marrow Transplant Certified Nurse.

With more than 30 years of experience and holding a variety of diverse roles in oncology, Katherine is recognized as a national nurse practitioner leader. She is currently working as an outpatient Advance Practice Provider responsible for the care of patients with hematological malignancies. Her clinical expertise includes hematologic malignancies, oncologic emergencies, CAR T-cell therapy, hematopoietic cell transplantation, survivorship, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, and book chapters. Ms. Byar co-edited the “ONS Cancer Basics third edition”. She also is an active member of the Oncology Nursing Society (ONS), and the Advanced Practitioner Society of Hematology and Oncology (APSHO).